Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts have been accepted for oral presentations at the 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results